. The purpose of this meeting was to discuss the appropriateness of current and new biostatistical methods in this field of drug development. easily adapted for "any" kind of two-sample tests, for example, nonparametric, dichotomous, censored, and so forth. Power was compared by a simulation study for selected conditions.
INTRODUCTION
at risk), or ordered categorical (eg, scored THIS ARTICLE DESCRIBES a simple closure testing procedure for dose-response relationships under real data conditions. Although this approach can be used for randomized clinical trials, pharmacological studies, and several toxicological studies, for example, reproductive toxicity, repeated toxicity studies (1) are considered here for analyzing the dose-response relationship. A oneway design: {C-, D,, . . , Dk) (with C-. . . negative control; D . . . dose group; with k not too small E 2,3,4) is assumed and multiple endpoints of a different scale, for example, approximate gaul3ian distributed (eg, body weight), a highly skewed distribution (eg, ASAT enzyme), dichotomous (eg, number of animals that diednumber of animals histopathological findings). Independent univariate analyses of the dose-response relationship should be performed, however, based on the same methodology. Only model-free approaches should be discussed here, because a priori in such "screening" studies a model for the profile cannot be assumed, even for a single endpoint.
The purpose of toxicological studies is safety assessment by comparing the doses to the concurrent negative control (many-toone comparisons). Traditionally, the classical hypotheses are used: null-hypothesis for no difference and alternative hypothesis for a difference (or one-sided for an increase). In this setting, type I error a represents producer's risk and type I1 error p consumer's risk.
A direct control of producer's risk (via a priori definition of a) is possible, but control of consumer's risk is of primary concern in proposed the reversing of the hypotheses in the Sense of a k-smple equivalence problem.
For this approach a threshold 6 must be de-Presented at the DIA Workshop "Statistical Methodolrisk assessment. ~h~~~f~~~ ~~~~ (2, 3) ogy in Non-Clinical and Toxicological Studies," March, [25] [26] [27] 1996 fined a priori or a posteriori. In toxicological studies with a primary endpoint, for example, number of revertants, such an approach can be used, as demonstrated for the Ames mutagenicity assay by Neuhauser and Hothorn (43) . In the multiple endpoint "screening" studies for repeated toxicity, however, this equivalence approach seems to be difficult. Therefore, the traditional hypotheses will be used here. In a k-sample design, the problem of multiple comparison exists. A general disadvantage of multiple comparison procedures is the loss of power (=increase of type I1 error) with an increasing number of comparisons. This increase of consumer's risk is exactly what should be avoided in safety studies. Therefore, this paper describes approaches with power as high as possible. Modifications of the closure principle will be used. But this represents a testing approach: a rejecuaccept decision only. Alternatively, the confidence interval could be used, including more information. This will be not discussed here. Power depends not only on the type of trend test, however, but also on the robustness against violation of the a priori assumptions: (9) , and Rom et al. (10) .
Choice of Contrast Tests
Trend tests can be distinguished according to their consideration of the dose levels into the test statistics: direct (respective as a transformed score) or qualitative only. It could be assumed that only qualitative consideration would yield an information loss and consequently a loss in power. This is not, however, true in general. On one hand, the dose levels may not be optimal and better scores should be used ( I l ) , and on the other hand dose levels in toxicological studies are often se- is also equivalent to multiple contrast tests.
One of the problems in application of trend tests is their reliance on the a priori unknown shape of the dose-response profile. For instance, using the concept of Pitman asymptotic relative efficacy (Ratio of sample sizes to guarantee the same power for a 3 0.6 0, n, * 00. or ratio of the power function in the point 01) the efficacy for several contrasts and selected dose-response profile contrasts in relation to the best power contrast can be compared according to Neuhiuser (17) (Table I ) .
From this table it can be concluded that the loss in power for the nonoptimal contrast test depending on the a priori unknown profile is large. Moreover, this loss in power occurs over a broad region of the noncentrality parameter 6. The power of Helmert and reverse Helmert contrasts (19) to see that for convex profiles, the Helmert contrast is much more powerful than reverse Helmert contrasts, and for concave profiles the opposite is true. This power difference is dramatic even for small shifts. It should be made clear that, in principle. the shape of the dose-response relationship is unknown a priori. Several concepts are now used to deal with this problem:
Ignoring this important fact: this is a commonly used practice but it is not acceptable in safety studies (due to a dramatic power loss). Looking at the data, characterizing a profile type, selection of the best suitable trend test represents one kind of hunting for significance, Bartholomew's (20) LRT test: a good version but limited to some ideal conditions, (26) . The correlation between two contrasts according to Bechhofer and Dunnett (27) in the variance homogeneity case is:
1
Contrast tests are simply defined by the linear combination of the mean values and univariate distributed: k with c c, = 0.
,dl
Researchers have a choice of contrast coefficients; several versions were described in the literature ( Table 2) It is simply true that if the contrast fits the empirical shape then the test power is optimal, for example, for a linear shape ,=o Fligner and Wolfe (19) Abelson and Tukey (24) Hothorn and Lehrnacher (25) Rorn et al. (10) Neuhauser (17) c,=-l, i=O,l,. . . the linear contrast, for a convex shape the Helmert contrast is optimal, and so forth. For the sake of simplicity and to allow for generalization to any kind of two-sample pairwise contrasts [C-vs. D,) will be used here according to Hothorn and Lehmacher (25) . This represents a special case of the principle of the a priori ordered test due to its importance according to Maurer et al. (28) . The question arises: using such a simple contrast does a power loss exist (ignoring the information between doses)'? In the parametric case (k = 4, n = 10) the power can be simply computed using noncentral t-distribution (Table 3 ). It can be concluded that the pairwise contrast is a simple and average powerful competitor to Helmert or reverse Helmert contrasts (representative of a broad class of alternatives between convex and concave profiles) in the case of an unknown doseresponse relationship.
Type of Order Restriction
On the one hand the dose response relationship can be assumed to be strictly monotonic and tests based on a total order restriction can be used, for example, pairwise contrasts, Helmert contrasts, reverse Helmert contrasts, or the ML-procedure according to Williams (14.15). On the other hand, in toxicology, downturns at high doses are possible. Procedures should be robust against this effect. In this situation MCPs without order restriction can be used, for example, in the parametric case Dunnett's (29) procedure (or its stepwise modifications). Alternatively, partial order restriction can be used, for example, Shaffer's (30) procedure. Based on ordered
TABLE 3 Power of Three Contrast Tests
Reverse Expected values Helrnert Helrnert Pairwise 0, 0.3, 0.6, 0.9 0, 0.6, 1.2, 1.8 0, 0, 1.8, 1.8 0, 0.9, 0.9, 0.9 0, 1.8, 1.8, 1.8 0, 0, 0, 0.45 0, 0, 0, 0.9 0, 0, 0, 1.35 0, 0, 0, 
SIMULATION RESULTS
A simulation study was performed to compare power between several approaches (all procedures are level-a methods), for example, k = 3 + 1, a = 0.05, ni = const = 10, N(p,,02 = l), pK = 0). Only results for selected dose-response profiles will be reported here ( Tables 4-7) . Even for monotonic profiles, a uniformly powerful procedure does not exist. A closure test using a painvise contrast reveals an average power. Adjustment for downturns causes a power loss, however, the power is higher than for the unrestricted alternative. For nonmonotonic profiles the power advantage of the adjusted procedure can be seen. For variance heterogeneity the power loss of the procedures based on mean square error can be clearly seen. Table 8 presents raw data from alkaline phosphatase measurement after six months in a repeated toxicity study in rats. It is easy to see that a possible downturn at high doses occurs and that the variances are not homogeneous.
EXAMPLE
Moreover, from historical controls it is known that the distribution of this endpoint is heavily skewed. Therefore, nonparametric Table  9 . This procedure reveals a significant global trend as well as a local decision on MED = 20 mgkg.
CONCLUSIONS
Real dose-response studies in toxicology are characterized by: 1. A priori unknown shape of the dose-pro-2. The possibility of downturns at high doses, 3. The possibility of (dose-dependent) variance heterogeneity and lack of balance, and 4. Endpoints other than those which are gau-Bian-distributed.
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